*
*Ototoxicity|9062008
*
*
is
damage|37782003
to the ear|117590005|1910005
(_oto-_
)
,
specifically
the cochlea|80169004|181187008
or
auditory nerve|8598002|113313006
and
sometimes
the vestibular system,|361533001
by a toxin.|80917008

It
is
commonly medication-|410942007
induced|16404004
;
ototoxic drugs|9062008|410942007
include|55919000
antibiotics|255631004
such as the aminoglycoside gentamicin,|324116004|387321007|324116004|411310000|14443002|387321007|14443002|411310000
loop diuretics|372691009
such as furosemide,|387475002
and
platinum-based chemotherapy agents|11996000|416608005|11996000|367336001|11996000|418836005|416608005|11996000|418836005|367336001
such as cisplatin.|387318005

A number of nonsteroidal anti-inflammatory drugs (NSAIDS)|410680006|372665008|410681005|372665008
have
also
been
shown
to
be
ototoxic.|9062008

This
can
result|394617004
in sensorineural hearing loss,|60700002
dysequilibrium,
or
both.

Either
may
be
reversible|35174006
and
temporary,|14803004
or
irreversible
and
permanent.|6934004

Antibiotics|255631004
in the aminoglycoside class,|324116004|258391009|14443002|258391009
such as gentamicin|387321007|411310000
and
tobramycin,|373548001
may
produce
cochleotoxicity
through a poorly understood mechanism.|556001|66216009|257544000

It
may
result|394617004
from antibiotic binding|255631004|257768005
to NMDA receptors|116647005
in the cochlea|80169004|181187008
and
damaging neurons|47220008
through excitotoxicity.

Aminoglycoside-induced production|324116004|16404004|14443002|16404004
of reactive oxygen species|11214006|24099007|69658003
may
also injure cells|4421005
of the cochlea.|80169004|181187008

Once-
daily dosing[4]|69620002
and
co-administration|413454004|416118004
of _N_-acetylcysteine[5]|387440002
may
protect
against aminoglycoside-induced ototoxicity.|324116004|16404004|9062008|14443002|16404004|9062008

The ototoxicity|9062008
of gentamicin|387321007|411310000
can
be
exploited
to
treat|395077000
some individuals|125676002|385435006
with M?ni?re's disease|258311008|228877007|64572001
by destroying
the inner ear,|302462009|181189006
which
stops|260890000
the vertigo attacks|399153001|216299002
but
causes|134198009
permanent deafness.[6]|6934004|6934004|343087000|6934004|8531006

Macrolide antibiotics,|105908007
including|55919000
erythromycin,|372694001
are
associated|47429007
with reversible ototoxic effects.|35174006|9062008|253861007

The underlying mechanism|257544000
of ototoxicity|9062008
may
be
impairment|40226000
of ion transport|48006008|57188001|48006008|360300001
in the stria vascularis.|88528000

Predisposing factors
include|55919000
renal impairment,|236423003
hepatic impairment,|32381004|40226000
and
recent organ transplantation.[7]|6493001|410653004|263903005

The loop diuretic furosemide|372691009|387475002
is
associated|47429007
with ototoxicity,|9062008
particularly
when
doses|277406006
exceed
240 mg|427264006
per hour.|258702006|286551008

The related compound ethacrynic acid|272151006|62105006|373536004|262094002|62105006|373536004
is
not
a sulfa drug|410942007
and
therefore
does
not
have
the same ototoxic effects|262126009|9062008|253861007
as furosemide.|387475002

Bumetanide|387498005
confers
a decreased risk|1250004|30207005|260400001|30207005|260371004|30207005
of ototoxicity|9062008
compared
to furosemide.[7]|387475002

Platinum-|84847000
containing|42504009
chemotherapeutic agents,|372688009|312059006
including|55919000
cisplatin|387318005
and
carboplatin,|386905002
are
associated|47429007
with cochleotoxicity
characterized
by high-frequency hearing loss|232326009
and
tinnitus|60862001
(ringing|112627000|257380004
in the ears|117590005|1910005
).

Ototoxicity|9062008
is
less frequently|276139006|70232002|263796003|70232002
seen
with the related compound oxaliplatin.|272151006|62105006|395814003|262094002|62105006|395814003

Cisplatin-induced ototoxicity|387318005|16404004|9062008
is
dose-dependent, typically|277406006|371154000|408102007|371154000
occurring|272120004
with doses|277406006
greater|263768009
than 60 mg/m2,|427264006|278077005
and
tend
to
occur|272120004
when
chemotherapy|416608005|367336001
is
given|419582001
every two weeks|420797005|258705008
compared
to every one week.|421379005|258705008|421379005|259038000

Cisplatin|387318005
and
related agents|272151006|260872001|262094002|260872001
are
absorbed
by the cochlear hair cells|52148002
and
result|394617004
in ototoxicity|9062008
through the production
of reactive oxygen species.|11214006|24099007|69658003

The decreased incidence|1250004|260400001|260371004
of oxaliplatin ototoxicity|395814003|9062008
has
been
attributed|246061005
to decreased uptake|1250004|258763004|260400001|258763004|260371004|258763004
of the drug|410942007
by cells|4421005
of the cochlea.|80169004|181187008

Administration|413454004|416118004
of amifostine|386923005
has
been
used|394850002
in attempts to
prevent
cisplatin-induced ototoxicity,|387318005|16404004|9062008
but
the American Society of Clinical Oncology|394592004
recommends
against its routine use.[12]|50811001|277889008|50811001|419385000

The vinca alkaloids,|61864009
including|55919000
vincristine,|387126006
are
also
associated|47429007
with reversible ototoxicity.[7]|35174006|9062008

Ototoxic effects|9062008|253861007
are
also
seen
with quinine|373497008
and
heavy metals|22907001
such as mercury|45262002
and
lead.|88488004

At high doses,|261829003
aspirin|387458008
and
other salicylates|74964007|350312004
may
also
cause|23981006|134198009
high-pitch tinnitus|51406002|60862001
and
hearing loss|343087000|15188001
in
both
ears,|117590005|1910005
typically reversible|35174006
upon discontinuation|278308006|410546004
of the drug.|410942007

The erectile dysfunction medications Viagra,|397803000|410942007
Levitra,
and
Cialis
have
also
been
reported|229059009|223458004
to
cause|23981006|134198009
hearing loss.[13]|343087000|15188001

Ototoxic chemicals|9062008|441900009
interact
with mechanical stresses|285655001
on the hair cells|52148002
of the cochlea|80169004|181187008
in different ways.|263735002

For organic solvents|349852009
such as Toluene,|67127007
styrene|84181009
or
xylene,|75495001
the combined exposure|89780004|71677004|89780004|24932003
with noise
increases|260366006
the risk|30207005
of hearing loss|343087000|15188001
in a synergistic manner [14] Heavy metals,|22907001
asphyxiants
and
endocrine disruptors|113331007
have
a variety
of interactions
as well.|20572008

Specific toxicity|69658003
limits|255469002
for combined exposures|89780004|71677004|89780004|242575009
are
not well established.|20572008|263748003|20572008|385645004

However,
given|419582001
the potential|30207005
for enhanced risk|30207005
of hearing loss,|343087000|15188001
the noise exposures|6300007
should
be
kept
below 85 decibels|259042002
and
the chemical exposures|441900009|71677004|441900009|242575009
should
be
below the recommended exposure limits|71677004|255469002|24932003|255469002
given|419582001
by agencies|224877003
such as OSHA,
NIOSH,
or
ACGIH.

Symptoms
of ototoxicity|9062008
include|55919000
partial|255609007
or
profound hearing loss,|343087000|15188001
vertigo,|399153001
and
tinnitus.[7]|60862001

Ototoxicity|9062008
is
the result|394617004
of the inner ear|302462009|181189006
being
poisoned|75478009|35331000
by a medication|410942007
which subsequently
causes|134198009
damage|37782003
to the cochlea,|80169004|181187008
vestibule,|279732009|181188003
semi-circular canals,|354652004|257577001
or
auditory/ vestibulocochlear nerve.|8598002|113313006

The structure
afflicted
with Ototoxicity also|9062008
affects|4065008
the symptoms
the patient|116154003
presents|52101004|246105001
with.

The cochlea|80169004|181187008
is
primarily
a hearing structure.|47078008|118230007

Within the inner ear,|302462009|181189006
it
is
the snail shaped shell|13732004|107644003|44537007|13732004|300842002|44537007|15838006|107644003|44537007|15838006|300842002|44537007
that
contains|42504009
several nerve endings|261028005|3057000|261782000|261028005|3057000|422117008|261028005|256864008|261782000|261028005|256864008|422117008
and
makes
hearing possible.|47078008|371930009|47078008|60022001|118230007|371930009|118230007|60022001

When
a patient|116154003
develops
ototoxicity|9062008
in the cochlea,|80169004|181187008
they
experience
hearing loss|343087000|15188001
that
can
range
from loss
of the high frequency pitch|51406002|260864003|51406002|272123002|27732004|51104005
ranges
to
complete|255594003
deafness.|343087000|8531006

Ototoxicity most commonly|9062008
presents|52101004|246105001
itself
with bilaterally symmetrical symptoms,|18772005
but
if
the symptoms
do
present|52101004|246105001
asymmetrically,
it
is
possible|371930009|60022001
the other ear|74964007|117590005|74964007|1910005
will
develop
the condition|260905004
at a later time.|260383002|410669006

The time frame|7389001
in which
the patient experiences hearing loss|116154003|116154003|343087000|116154003|15188001
remains
debatable
as the symptoms
which patients|116154003
suffer
vary
greatly.

In many instances,
symptoms
are
temporary|14803004
;
however,
there
are
many cases|260396001|398241000|260396001|413769002
in which
the hearing loss|343087000|15188001
is
permanent.|6934004

The cochlea|80169004|181187008
can
also
develop
tinnitus|60862001
from ototoxicity,|9062008
causing|23981006
a ringing sound|112627000|112627000|68325009|257380004|257380004|68325009
in the ears|117590005|1910005
which only|50607009|420295001
the patient|116154003
can
hear.|47078008

The vestibule|279732009|181188003
and
semi-circular canal|354652004|3262009|354652004|257577001
are
inner-ear components|302462009|246093002|181189006|246093002
which
comprise
the vestibular system,|361533001
another area|42798000
of the ear|117590005|1910005
affected|247591002|248448006
by ototoxicity.|9062008

Due to the difference|263735002
in the function|246464006
of these structures,
ototoxic poisoning|9062008|75478009
affects|4065008
the patient differently|116154003
than
in the case|398241000
of cochlear damage.|80169004|37782003

The vestibule|279732009|181188003
is
where the two types|420797005|261664005
of otolith organs|1610007|410653004
are
housed|414418009
:
the saccule,|54458009|279827000
which
points
vertically
and
detects|260373001
vertical acceleration,|33096000|285659007
and
the utricle,|81955007|84140001|279817006
which
points
horizontally
and
detects|260373001
horizontal acceleration.|24020000|285659007

The otolith organs|1610007|410653004
detect|260373001
the head?s position|304631003
with respect
to gravity|91071007
when
the body|279495008|123037004
is
static,|257390007
the head?s movement|69536005|255324009|302548004|255324009
in an angular|1483009
or
tilted direction,|260672003
and
pitch changes|51104005|243326001|51104005|263703002
during any linear motion|50009006|56219004
of the head.|69536005|302548004

The saccule|54458009|279827000
and
utricle|81955007|84140001|279817006
work|261041009
together to
detect|260373001
different motions|263735002|56219004|263735002|272149007
that
the brain later|12738006|258335003
integrates
to correctly
determine
exactly
where the head|69536005|302548004
is
and
how
and
where it
is
moving.

The vestibule|279732009|181188003
and
the semi-circular canals|354652004|257577001
work|261041009
together to
detect|260373001
all forms|246176004
of head movement.|69536005|255324009|302548004|255324009

The semi-circular canals|354652004|257577001
are
three bony structures|421291004|272673000
that
are
filled
with fluid.|32457005|33463005|255765007

Just
as the vestibule,|279732009|181188003
the primary purpose|63161005|363675004|261424001|363675004
of the canals|257577001
is
to
detect|260373001
movement.|255324009

Each canal|3262009|257577001
is
oriented independently|311552005
at right angles|24028007|1483009
from the others,|74964007
enabling|225791005
detection
of movement|255324009
in any plane.|260225008

The posterior canal|255551008|3262009|255551008|257577001
detects|260373001
rolling motion,|56219004
or
motion|56219004
about the X axis|39976000|388282002
;
the anterior canal|255549009|3262009|255549009|257577001
detects|260373001
pitch,|51104005
or
motion|56219004
about the Y axis|39976000|388282002
;
the horizontal canal|24020000|3262009|24020000|257577001
detects|260373001
yaw motion,|70647001|56219004
or
motion|56219004
about the Z axis.|39976000|388282002

When
a medication|410942007
causes|134198009
an ototoxic reaction|9062008|263851003
in
either
the vestibule|279732009|181188003
or
semi-circular canals,|354652004|257577001
the patient suffers|116154003
from problems|55607006
in balance|249982003|78933003|282295000
and
orientation|43173001|311552005
rather than
hearing issues.|47078008|55607006|118230007|55607006

Symptoms
in these organs|410653004
present|52101004|246105001
as vertigo,|399153001
difficulties|371157007
walking|129006008
at night,|2546009
and
disequilibrium,
oscillopsia|246650003
among other balance related problems.|74964007|298313002|272151006|74964007|298313002|262094002

Each
of these problems|55607006
is
directly
related|272151006|262094002
to balance|249982003|78933003|282295000
and
the mind
being
confused|286933003
with the direction|260672003
of motion|56219004
or
lack|41277001
of motion.|56219004

Because
both the vestibule|279732009|181188003
and
semi-circular canals|354652004|257577001
transmit|60117003
information
to the brain|12738006|258335003
about movement,|255324009
when
these
are
poisoned|75478009|35331000
,
they
are
unable to|371151008
function|246464006
properly
which
results|394617004
in miscommunication
with the brain.|12738006|258335003

When
the vestibule|279732009|181188003
and/or
semi-circular canals|354652004|257577001
are
affected|247591002|248448006
by ototoxicity,|9062008
the eye|81745001|244486005
can
also
be
affected.|247591002|248448006

Nystagmus|563001
and
oscillopsia|246650003
are
two|420797005
conditions|78326006|260905004
that
overlap|24846002
the vestibular|279732009|181188003
and
ocular systems.|81745001|246333005|281004000|246333005|246333005

These symptoms
cause|23981006|134198009
the patient to|116154003
have
difficulties|371157007
with seeing|281004000
and
processing images.|415178003

The body subconsciously|279495008|123037004
tries
to
compensate|17275008
for the imbalance signals
being
sent
to the brain|12738006|258335003
by trying to
obtain|398092000
visual cues to|255374006
support|9096001|243114000
the information
it
is
receiving.

This results|394617004
in
that dizziness|404640003|399153001
and ?woozy? feeling patients|404640003|285854004|116154003|404640003|116154003
use|277889008|419385000
to
describe
conditions|260905004
such as oscillopsia|246650003
and
vertigo.[16]|399153001

The auditory/vestibulocochlear nerve,|8598002|113313006
or
cranial nerve VIII,|8598002
is
the least afflicted component|276139006|246093002|263796003|246093002
of the ear|117590005|1910005
when
ototoxicity|9062008
arises|68727004
,
but
if
the nerve|3057000|256864008
is
affected,|247591002|248448006
the damage|37782003
is
most often permanent.|4757001|70232002|6934004

Cranial nerve VIII ?|8598002
has
a vestibular part|279732009|260726005|181188003|260726005
which
functions|246464006
in balance,|249982003|78933003|282295000
equilibrium,|249982003
and
orientation|43173001|311552005
in three-dimensional space,|264672008
and
a cochlear part|80169004|260726005
which
functions|246464006
in hearing."[17]|47078008|118230007
Despite the vestibular|279732009|181188003
or
cochlear structures|80169004
functioning|246464006
normally,
affliction
of the nerve effectively|3057000|256864008
arrests|397829000|6155003
communication|263536004
between these structures
and
the brain.|12738006|258335003

Symptoms
present|52101004|246105001
similar
to those resulting|42752001
from vestibular|279732009|181188003
and
cochlear damage,|80169004|37782003
including|55919000
tinnitus,|60862001
ringing|112627000|257380004
of the ears,|117590005|1910005
difficultly walking,|129006008
deafness,|343087000|8531006
and
balance|249982003|78933003|282295000
and
orientation issues.[17]|43173001|55607006|311552005|55607006

No specific treatment|69658003|276239002|69658003|416118004
is
available,|103328004
but
immediate withdrawal|88694003|49499008
of the drug|410942007
may
be
warranted
in cases|398241000|413769002
where the consequences|103332005
of
doing
so|223528007
are
less severe|276139006|24484000|263796003|24484000
than the consequences|103332005
of the ototoxicity.[7]|9062008

It
is
difficult to|52925006
distinguish
between nerve damage|57182000
and
structural damage|37782003
due to similarity
of the symptoms.

Often ototoxicity diagnoses|70232002|9062008|439401001
result|394617004
from ruling out|10828004
all other possible sources|74964007|371930009|260753009|74964007|60022001|260753009
of hearing loss|343087000|15188001
and
is
the catchall explanation
for the sudden problem.|255363002|55607006

Treatment options|276239002|416118004
vary
depending
on the patient|116154003
and
the diagnosis.|439401001

Some patients only|116154003
experience
temporary symptoms,|14803004
which
do
not
require
drastic treatment|276239002|416118004
while
other patients|74964007|116154003
can
be
treated|28995006
with medication.|410942007

Physical therapy|91251008
remains
particularly useful
with regaining balance|249982003|78933003|282295000
and
walking abilities.|282097004

Cochlear implants|43252007|359612003
are
sometimes
an option
as well to|20572008
restore
hearing.|47078008|118230007

However,
these treatments|276239002
are
more often|242762006|70232002
made
in an effort to|19487008
make
the patient|116154003
as comfortable
as possible|371930009|60022001
and
to
help
them
cope|405056001
with the symptoms,
not to
cure
them
of the disease|64572001
or
damage|37782003
caused|23981006|134198009
by ototoxicity.|9062008

There
is
no cure
or
restoration capability|260938008
if
the damage|37782003
becomes
permanent.[18][19]|6934004

M
:
EAR|117590005|1910005

anat(e/p/phys/devp

noco/cong,
epon

proc,
drug|410942007
(S2

